Who are NaluBio, Inc.'s investors?

NaluBio, Inc.'s investors include Bonaventure Equity, LLC, Flybridge Capital Partners, Portfolia, Golden Seeds.

How much funding has NaluBio, Inc. raised?

NaluBio, Inc. has disclosed $4.8M raised across 1 round.

Where is NaluBio, Inc. headquartered?

NaluBio, Inc. is headquartered in San Francisco, US.

NaluBio, Inc.

San Francisco, US · Founded 2019 · Delaware corporation · 14 employees on LinkedIn · 4 known investors

Nalu Bio develops an AI-powered drug discovery platform targeting the endocannabinoid system to create therapeutics for inflammatory, immune, and metabolic diseases. The company designs novel, non-addictive ECS-based solutions for patients with conditions like chronic pain, sleep disorders, and endometriosis.

AI & Machine Learning Biotech Healthtech Medical Devices

Founders & leadership

NaluBio, Inc. was founded in 2019 by Caitlyn Krebs, Phyllis Whiteley, Randall Ussery, Phyllis E. Whiteley, and Randall S. Ussery.

Caitlyn KrebsCo-founder + CEO

Phyllis WhiteleyCo-founder + Board Member

Randall UsseryCo-founder + Board Member

Phyllis E. WhiteleyCo-founder

Randall S. UsseryCo-founder

Howard GoodwinNamed on SEC filing

Investors · 4

Bonaventure Equity, LLCRaleigh

Flybridge Capital PartnersNew York · $250K – $10M

PortfoliaSan Mateo · $10K

Golden SeedsreportedFlushing · $250K – $2M

Reported raises · per SEC filings

Form D private placements

$4.8M disclosed across 1 round · 2023

▶$4.8MraisedMar 2023 · 11 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Phyllis E. WhiteleyExecutive Officer, Director
Howard GoodwinDirector
Randall S. UsseryDirector
Caitlyn KrebsExecutive Officer, Director

Offering amount: $17.1M
Amount sold: $4.8M
First sale: Jan 2023
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Nalu6 shared keywordsNalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain. The system consists of an implanted microstimulator, a separate electrode array, and an externally worn, battery-free therapy disc, offered as a drug-free treatment option to patients through their doctors.

Companies competing with NaluBio, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does NaluBio, Inc. do?: Nalu Bio develops an AI-powered drug discovery platform targeting the endocannabinoid system to create therapeutics for inflammatory, immune, and metabolic diseases. The company designs novel, non-addictive ECS-based solutions for patients with conditions like chronic pain, sleep disorders, and endometriosis.
Who founded NaluBio, Inc.?: NaluBio, Inc. was founded by Caitlyn Krebs, Phyllis Whiteley, Randall Ussery, Phyllis E. Whiteley, Randall S. Ussery in 2019.
Who are NaluBio, Inc.'s investors?: NaluBio, Inc.'s investors include Bonaventure Equity, LLC, Flybridge Capital Partners, Portfolia, Golden Seeds.
How much funding has NaluBio, Inc. raised?: NaluBio, Inc. has disclosed $4.8M raised across 1 round.
Where is NaluBio, Inc. headquartered?: NaluBio, Inc. is headquartered in San Francisco, US.